Skip to navigation Skip to content

News release

Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico

Mar 27, 2025

Mexico City - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Vida y Familia México, I.A.P. ("VIFAC") to support programs that promote maternal and child health and address health disparities.

Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund focuses on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health. Apotex has had a presence in Mexico since 1996.

VIFAC is the third Apotex Global Health Access Fund grant recipient, and the first in Mexico. The organization will receive $100,000 (~1,400,000 MXN) annually over the next three years to support their comprehensive maternal and child health services, aiming to improve health outcomes and address social determinants of health.

"We are thrilled to announce this grant to Vida y Familia, which underscores our commitment to addressing health disparities," said Alok Kanti, President, Apotex International. "By supporting organizations like VIFAC, we aim to make positively impact maternal and child health and the well-being of families, supporting them on their health journeys."

"We are incredibly grateful to Apotex for their commitment to our mission of improving the lives of mothers and children in need," said Gabriela Vilchis, General Director of VIFAC. "This support will help us expand our reach and enhance the services that we provide in helping reduce maternal and infant mortality in Mexico."

In its inaugural year, the Apotex Global Health Access Fund focuses on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million.  

For more information about Vida y Familia México, I.A.P., please visit www.vifac.org

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.

Media inquries

Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.

Contact our media team

Latest news

  • Sep 18, 2026

    Apotex Health Corp. announces closing of upsized bought deal secondary offering

    Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").

  • Sep 15, 2026

    Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million

    Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").

  • Sep 15, 2026

    Apotex Health Corp. announces $750 million bought deal secondary offering

    Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.